Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
OBJECTIVE
To assess the association of serum anti-p53 antibodies and overexpression of tumor p53 protein with survival and prognostic factors in patients with urinary bladder tumors.


METHODS
Seventy-six patients with transitional cell carcinoma of the urinary bladder were assessed prospectively (Ta, 18; T(1), 30; > or =T(2), 28). Serum anti-p53 antibodies were detected by enzyme-linked immunosorbent assay. Tumor p53 gene overexpression was assessed by immunohistochemical staining. The mean follow-up time was 34 months.


RESULTS
Serum anti-p53 antibodies were positive in 25 patients (33%). Overexpression of tumor p53 protein was positive in 41 patients (54%). There was an association between the presence of serum anti-p53 antibodies and tumor p53 gene overexpression (P = 0.001). The total survival of the patients with positive serum anti-p53 antibodies was shorter than the patients with positive tumor p53 gene overexpression (P < 0.001, P = 0.344, respectively). In the multivariate survival analysis, both tumor stage and serum-p53 antibodies were found to be independent survival predictors (P = 0.004, P = 0.006, respectively).


CONCLUSIONS
Serum anti-p53 antibody positive tumors had a worse prognosis than those with negative serum levels, regardless of the p53 status of the tumor.
Gumus
Eyup
E
2nd Urology Clinic, Sisli Etfal Training and Research Hospital, Istanbul, Turkey. eyupg@superonline.com
Erdamar
Sibel
S
Demirel
Gulderen
G
Horasanli
Kaya
K
Kendirci
Muammer
M
Miroglu
Cengiz
C
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000974:Antibodies, Antinuclear / Q000097:blood*; D002295:Carcinoma, Transitional Cell / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D016022:Case-Control Studies; D005260:Female; D005500:Follow-Up Studies; D015870:Gene Expression; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000276:immunology*; D001749:Urinary Bladder Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology
D000974:Antibodies, Antinuclear; D016159:Tumor Suppressor Protein p53